DeepCure Showcases Powerful New Treatment for RA That Outshines Etanercept
DeepCure's Groundbreaking Presentation on DC-9476
Recently, DeepCure, a pioneering therapeutics company leveraging artificial intelligence to develop innovative drugs for immune and inflammatory diseases, announced significant findings regarding its selective BRD4 (BD2) inhibitor, DC-9476. The data reveals that DC-9476 performs better than the conventional anti-TNF-? treatment known as etanercept in mouse models of rheumatoid arthritis (RA).
Understanding Rheumatoid Arthritis
Rheumatoid arthritis is a chronic autoimmune disorder characterized by a particularly aggressive inflammation of the joints. One of the key players in the progression of this condition is activated macrophages, which generate inflammatory cytokines such as TNF-?, IL-1?, and IL-6, leading to joint destruction and considerable pain for those affected.
The Power of DC-9476
DC-9476 has undergone rigorous evaluation through various preclinical studies aiming to establish its efficacy as a potential treatment for RA. The in vitro assessments showed that when human macrophages were stimulated, DC-9476 effectively reduced IL-6 production, proving to be more potent than tofacitinib, a known Jak-2 inhibitor currently in use for RA cases.
In Vivo Findings of Efficacy
The impressive efficacy of DC-9476 was further demonstrated in two different mouse models. First, in an inflammatory model triggered by lipopolysaccharide (LPS), DC-9476 significantly decreased the levels of serum IL-6 and TNF-?. In the collagen antibody-induced arthritis model, which closely mirrors macrophage-driven RA, DC-9476 led to over an 80% reduction in clinical disease scores. This was substantially better than etanercept, which achieved only a 47% reduction in the same context. Notably, throughout these studies, DC-9476 exhibited no observable toxicity.
Combination Therapy Benefits
Moreover, it was discovered that when DC-9476 was combined with etanercept, there were substantial enhancements in therapeutic outcomes compared to each treatment being administered alone. This indicates that DC-9476 could serve as not only a standalone treatment but also as a powerful adjunct in combination therapies for RA patients.
Details of an Important Presentation
DeepCure will present these exciting findings in a poster titled: "Novel, Selective BRD4 (BD2) Inhibitor DC-9476 Demonstrates a Potent Anti-inflammatory Mechanism." This presentation is slated for October 19 at 10:25 am local time, with Dr. Michal Segal-Salto, Senior Director of Biology at DeepCure, as the presenter.
Kfir Schreiber, CEO & Co-Founder of DeepCure, commented on this significant moment: "This is the first time we are presenting in vivo data in animal models of RA for DC-9476, which demonstrates its potential as a novel oral monotherapy or combination therapy for patients. In addition, this selective BRD4 (BD2) inhibitor reduced key inflammatory cytokines that could be used as biomarkers of target engagement in future clinical trials."
About DeepCure and Its Vision
DeepCure is dedicated to advancing novel therapeutic solutions for inflammation and autoimmune diseases. Founded by a group of MIT researchers, the company harnesses the power of artificial intelligence along with cutting-edge technologies in small molecule discovery. Based in Boston, the collaborative efforts of its engineers, chemists, and biologists focus on addressing complex issues that can lead to transformative impacts on patient health and outcomes.
Frequently Asked Questions
What is DC-9476?
DC-9476 is a selective BRD4 (BD2) inhibitor developed by DeepCure aimed at treating rheumatoid arthritis.
How does DC-9476 compare to standard treatments?
In preclinical studies, DC-9476 has shown superior efficacy compared to etanercept, the current anti-TNF-? treatment.
What are the benefits of combination therapy with DC-9476?
Combining DC-9476 with etanercept yielded significantly better results than using either treatment alone.
When and where will the presentation take place?
The presentation will occur on October 19 at 10:25 am local time, highlighting the promising findings of DC-9476.
What is DeepCure's mission?
DeepCure aims to discover and develop novel drugs using AI to transform the treatment landscape for autoimmune and inflammatory diseases.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Significant New Share Offering by DSV A/S Bolsters Financial Growth
- Samsung Launches Next-Gen SSDs for Enhanced AI Performance
- Alpha Cognition's New Leadership: Aiming for Breakthroughs in Neurodegenerative Therapy
- AI's Role in Transforming the ELISA Market by 2028
- Agenus Inc. Securities Fraud Lawsuit Offers Investor Recourse
- Vale's Strategic Expansion of Copper Production and Investments
- Manganese Mining Sector Set for Dramatic Growth by USD 10.94 Billion
- 79North's Strategic Debt Settlement: An Overview
- Empower Your Health with Foodom's New FSA/HSA Benefits
- Spire Global, Inc. Faces Securities Fraud Lawsuit Chance for Investors
Recent Articles
- Join the Excitement at the Annual Yugabyte Distributed SQL Summit
- Unlocking Information Quality: A Symposium for Everyone
- Vir Biotechnology's Upcoming Engagements and Innovations in Healthcare
- The Growing IT Skills Gap: Insights for UK Businesses
- Unlocking Your Business Potential: The PagerDuty Advantage
- Markel Group Plans Exciting 2025 Reunion with Engaging Events
- Chinese Central Bank Embarks on Bond Purchasing Strategy
- Tradeswomen Conference Unites Female Iron Workers in a Major Event
- Brian Scott Takes the Helm as CFO and COO at AMN Healthcare
- New Insights on Targeting Toxic Gain of Function Mutations
- VyStar Credit Union Expands Workforce with New Opportunities
- Ultragenyx Pharmaceutical Shows Promise in Gene Therapy Progress
- Impact of Healthcare Costs on American Voting in 2024
- NASA's New Astrophysics Missions Set to Unlock Cosmic Mysteries
- StandardAero's IPO Fuels New Financial Strategies and Growth
- Sustainability Education: A Must-Have for America’s Schools
- TMTG Faces Legal Challenges Amid Expansion Efforts
- Canadian Physician Consensus: Urgent Need for AI Regulations
- SWK Holdings Corporation Faces Board Change as Pennington Resigns
- Security Camera Demand Grows Amid Election Integrity Concerns
- Virpax Pharmaceuticals Expands Financial Negotiation Options
- euNetworks Unveils Advanced Fibre Route Boosting Connectivity
- Sportradar Appoints Michael C. Miller as Legal Chief
- Discover the Latest Innovations with Oura Ring 4 Launch
- SMART Global Holdings Announces 2025 Shareholder Meeting Plans
- TCarta Marine Enhances Maritime Safety with Satellite Solutions
- Alzamend Neuro Secures $6.5 Million Through ATM Offering
- Zyxel Launches Advanced Wi-Fi 7 Gateways for Service Providers
- Ultragenyx Advances Gene Therapy Study with Positive Results
- Transforming TV Advertising: The Launch of Annika Audience™
- Understanding the Impacts of Federal Reserve's Losses
- Starbucks Takes Bold Steps Towards a Sustainable Coffee Future
- Market Volatility: U.S. Stocks Decline Amid Sector Losses
- Phreesia and Ad Council's Impact on Mental Health Engagement
- CALQUENCE® Receives Priority Review in the US for MCL Treatment
- Herbalife Achieves GUINNESS WORLD RECORDS Title in Fitness Event
- D-Wave Evolves with Service-Level Agreements for Quantum Cloud
- Jabil's Strategic Acquisition of Mikros Technologies for Enhanced AI Cooling
- Aldeyra Therapeutics Advances Reproxalap for Dry Eye Disease
- Harrow Revives TRIESENCE®: A Breakthrough for Eyecare
- Laser Photonics and Brokk Showcase Innovative Robotic Solutions
- Handling Cyberbullying: Empowering Teens in Modern Times
- Vecima Networks Enhances Connectivity During Crisis Response
- TransAct Technologies Gears Up for Major Events in Las Vegas
- CDK Unveils Innovative Certification Program for Dealerships
- Onconetix Secures $2 Million in Financing for Growth Plans
- GoldenTV Unveils Exciting New Programs for 2024-2025 Season
- AMN Healthcare Welcomes Brian Scott as New CFO and COO
- ProPetro Sets Date for Third Quarter 2024 Financial Discussion
- TILT Holdings Welcomes New Board Member Amid Transition